

Anne T Nies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/891020/publications.pdf>

Version: 2024-02-01

90
papers

7,800
citations

61857

43
h-index

56606

83
g-index

95
all docs

95
docs citations

95
times ranked

6998
citing authors

#	ARTICLE	IF	CITATIONS
1	Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1999, 1461, 377-394.	1.4	681
2	A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, G156-G164.	1.6	479
3	Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide. <i>Journal of Biological Chemistry</i> , 2000, 275, 23161-23168.	1.6	462
4	Expression and immunolocalization of the multidrug resistance proteins, MRP1 and MRP6 (ABCC1 and ABCC6), in human brain. <i>Neuroscience</i> , 2004, 129, 349-360.	1.1	345
5	The apical conjugate efflux pump ABCC2 (MRP2). <i>Pflugers Archiv European Journal of Physiology</i> , 2007, 453, 643-659.	1.3	329
6	Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. <i>Hepatology</i> , 2009, 50, 1227-1240.	3.6	316
7	Organic Cation Transporters (OCTs, MATEs), In Vitro and In Vivo Evidence for the Importance in Drug Therapy. <i>Handbook of Experimental Pharmacology</i> , 2011, , 105-167.	0.9	312
8	Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. <i>Hepatology</i> , 2003, 38, 374-384.	3.6	306
9	ABCC Drug Efflux Pumps and Organic Anion Uptake Transporters in Human Gliomas and the Blood-Tumor Barrier. <i>Cancer Research</i> , 2005, 65, 11419-11428.	0.4	266
10	Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. <i>Clinical Pharmacokinetics</i> , 2015, 54, 709-735.	1.6	207
11	Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. <i>Genome Medicine</i> , 2013, 5, 1.	3.6	198
12	Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. <i>International Journal of Cancer</i> , 2005, 115, 359-367.	2.3	165
13	Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2001, 94, 492-499.	2.3	163
14	Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 126-135.	4.0	150
15	Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 39, 693-702.	1.8	149
16	Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs). <i>PLoS ONE</i> , 2011, 6, e22163.	1.1	140
17	Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in dubin-johnson syndrome. <i>Hepatology</i> , 2000, 32, 1317-1328.	3.6	132
18	A Naturally Occurring Mutation in the SLC21A6 Gene Causing Impaired Membrane Localization of the Hepatocyte Uptake Transporter. <i>Journal of Biological Chemistry</i> , 2002, 277, 43058-43063.	1.6	127

#	ARTICLE	IF	CITATIONS
19	DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. <i>Genome Medicine</i> , 2011, 3, 82.	3.6	124
20	Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 545-568.	1.5	114
21	A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G165-G174.	1.6	108
22	Detection of the Human Organic Anion Transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in Liver and Hepatocellular Carcinoma. <i>Laboratory Investigation</i> , 2003, 83, 527-538.	1.7	105
23	Organic Anion Transporters and Their Implications in Pharmacotherapy. <i>Pharmacological Reviews</i> , 2012, 64, 421-449.	7.1	105
24	A phosphotyrosine switch regulates organic cation transporters. <i>Nature Communications</i> , 2016, 7, 10880.	5.8	100
25	Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 376, 449-461.	1.4	99
26	PROSTANOID TRANSPORT BY MULTIDRUG RESISTANCE PROTEIN 4 (MRP4/ABCC4) LOCALIZED IN TISSUES OF THE HUMAN UROGENITAL TRACT. <i>Journal of Urology</i> , 2005, 174, 2409-2414.	0.2	93
27	Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. <i>Neuroscience</i> , 2006, 137, 1247-1257.	1.1	90
28	DNA Methylation of the <i>SLC16A3</i> Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome. <i>Clinical Cancer Research</i> , 2013, 19, 5170-5181.	3.2	90
29	Characterization of the 5' flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison with the multidrug resistance protein 3 (MRP3) gene. <i>FEBS Journal</i> , 2000, 267, 1347-1358.	0.2	87
30	Export pumps for anionic conjugates encoded by MRP genes. <i>Advances in Enzyme Regulation</i> , 1999, 39, 237-246.	2.9	86
31	Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). <i>Pharmacogenetics and Genomics</i> , 2004, 14, 213-223.	5.7	84
32	Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. <i>Hepatology</i> , 2018, 67, 1609-1619.	3.6	83
33	Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF-B. <i>Hepatology</i> , 1998, 28, 1332-1340.	3.6	82
34	Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 904-932.	4.0	72
35	Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family. <i>Advances in Enzyme Regulation</i> , 2000, 40, 339-349.	2.9	71
36	Structural requirements for the apical sorting of human multidrug resistance protein 2 (ABCC2). <i>FEBS Journal</i> , 2002, 269, 1866-1876.	0.2	64

#	ARTICLE	IF	CITATIONS
37	MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, G522-G531.	1.6	59
38	Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. <i>Drug Metabolism Reviews</i> , 2011, 43, 499-523.	1.5	59
39	Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1). <i>Clinical Cancer Research</i> , 2014, 20, 985-994.	3.2	54
40	Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. <i>Archives of Toxicology</i> , 2016, 90, 1555-1584.	1.9	54
41	The role of membrane transporters in drug delivery to brain tumors. <i>Cancer Letters</i> , 2007, 254, 11-29.	3.2	53
42	Immunolocalization of Multidrug Resistance Protein 5 in the Human Genitourinary System. <i>Journal of Urology</i> , 2002, 167, 2271-2275.	0.2	52
43	Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. <i>Clinical Pharmacokinetics</i> , 2016, 55, 507-524.	1.6	52
44	Role of ABC Transporters in Fluoropyrimidine-Based Chemotherapy Response. <i>Advances in Cancer Research</i> , 2015, 125, 217-243.	1.9	43
45	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. <i>Cancer Research</i> , 2017, 77, 2102-2111.	0.4	41
46	Solute carrier transporter and drug-related nephrotoxicity: the impact of proximal tubule cell models for preclinical research. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 395-408.	1.5	40
47	Characterization of the breast cancer resistance protein (BCRP/ <i>ABCG2</i>) in clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 3181-3193.	2.3	40
48	Purification of the human apical conjugate export pump MRP2. Reconstitution and functional characterization as substrate-stimulated ATPase. <i>FEBS Journal</i> , 1999, 265, 281-289.	0.2	39
49	Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma. <i>Drug Metabolism and Disposition</i> , 2014, 42, 2033-2040.	1.7	38
50	Retigabine/Ezogabine, a KCNQ/K _V 7 channel opener: pharmacological and clinical data. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1807-1816.	0.9	35
51	Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors. <i>Pharmacogenomics Journal</i> , 2016, 16, 341-351.	0.9	34
52	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	33
53	Regulation and translocation of ATP-dependent apical membrane proteins in rat liver. <i>American Journal of Physiology - Renal Physiology</i> , 1997, 272, G1041-G1049.	1.6	31
54	Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process. <i>Molecular Pharmaceutics</i> , 2018, 15, 3557-3572.	2.3	30

#	ARTICLE	IF	CITATIONS
55	MRP2, THE APICAL EXPORT PUMP FOR ANIONIC CONJUGATES. , 2003, , 423-443.		29
56	Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Scientific Reports, 2016, 6, 29930.	1.6	29
57	Stratified medicine for the use of antidiabetic medication in treatment of type <scp>II</scp> diabetes and cancer: where do we go from here?. Journal of Internal Medicine, 2015, 277, 235-247.	2.7	28
58	Genetic Biomarkers in Epilepsy. Neurotherapeutics, 2014, 11, 324-333.	2.1	26
59	Multidrug and toxin extrusion proteins as transporters of antimicrobial drugs. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1565-1577.	1.5	24
60	MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma. Oncotarget, 2015, 6, 30615-30627.	0.8	24
61	Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. Clinical Pharmacology and Therapeutics, 2020, 107, 227-237.	2.3	23
62	Testing association of rare genetic variants with resistance to three common antiseizure medications. Epilepsia, 2020, 61, 657-666.	2.6	22
63	Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. Pharmacogenomics, 2020, 21, 325-335.	0.6	21
64	Histamine transport and metabolism are deranged in salivary glands in Sjogren's syndrome. Rheumatology, 2013, 52, 1599-1608.	0.9	20
65	Human Pregnane X Receptor Genotype of the Donor but Not of the Recipient Is a Risk Factor for Delayed Graft Function After Renal Transplantation. Clinical Pharmacology and Therapeutics, 2012, 91, 905-916.	2.3	17
66	Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters. Pharmaceutics, 2021, 13, 369.	2.0	14
67	Raman Imaging and Fluorescence Lifetime Imaging Microscopy for Diagnosis of Cancer State and Metabolic Monitoring. Cancers, 2021, 13, 5682.	1.7	11
68	Organic cation transporter pharmacogenomics and drug-drug interaction. Expert Review of Clinical Pharmacology, 2010, 3, 707-711.	1.3	10
69	The fruit fly <i>Drosophila melanogaster</i> as an innovative preclinical ADME model for solute carrier membrane transporters, with consequences for pharmacology and drug therapy. Drug Discovery Today, 2018, 23, 1746-1760.	3.2	10
70	Inhibition of organic cation transporter (OCT) activities by carcinogenic heterocyclic aromatic amines. Toxicology in Vitro, 2019, 54, 10-22.	1.1	10
71	Two experts and a newbie: [18F]PARPi vs [18F]FTT vs [18F]FPyPARP—a comparison of PARP imaging agents. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 834-846.	3.3	10
72	The importance of drug transporter characterization to precision medicine. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 361-365.	1.5	9

#	ARTICLE	IF	CITATIONS
73	Clinically Relevant OATP2B1 Inhibitors in Marketed Drug Space. <i>Molecular Pharmaceutics</i> , 2020, 17, 488-498.	2.3	9
74	Inhibition of organic cation transporter 3 activity by tyrosine kinase inhibitors. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 919-929.	1.0	9
75	Increased protein kinase A regulatory subunit content and cGMP binding in erythrocyte membranes in liver cirrhosis. <i>Journal of Hepatology</i> , 2004, 40, 766-773.	1.8	8
76	Direct Automated MALDI Mass Spectrometry Analysis of Cellular Transporter Function: Inhibition of OATP2B1 Uptake by 294 Drugs. <i>Analytical Chemistry</i> , 2020, 92, 11851-11859.	3.2	8
77	Genetic and Epigenetic Regulation of Organic Cation Transporters. <i>Handbook of Experimental Pharmacology</i> , 2021, 266, 81-100.	0.9	8
78	Multidrug Resistance Proteins of the ABCC Subfamily. , 0, , 263-318.		7
79	Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins. <i>British Journal of Pharmacology</i> , 2021, 178, 1459-1474.	2.7	7
80	Functional characterization of common protein variants in the efflux transporter ABCC11 and identification of T546M as functionally damaging variant. <i>Pharmacogenomics Journal</i> , 2016, 16, 193-201.	0.9	6
81	Hepatic Expression of the Na ⁺ -Taurocholate Cotransporting Polypeptide Is Independent from Genetic Variation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7468.	1.8	6
82	Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin". <i>Science Translational Medicine</i> , 2017, 9, .	5.8	4
83	Differential <i>in vitro</i> interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters. <i>Xenobiotica</i> , 2021, 51, 467-478.	0.5	3
84	The Membrane Transporter OAT7 (SLC22A9) Is Not a Susceptibility Factor for Osteoporosis in Europeans. <i>Frontiers in Endocrinology</i> , 2020, 11, 532.	1.5	2
85	Effects of a Common Eight Base Pairs Duplication at the Exon 7-Intron 7 Junction on Splicing, Expression, and Function of OCT1. <i>Frontiers in Pharmacology</i> , 2021, 12, 661480.	1.6	2
86	Transport of Bilirubin Conjugates across Hepatocellular Membrane Domains and the Conjugated Hyperbilirubinemia of Dubin-Johnson Syndrome. , 2004, , 195-210.		0
87	Membrane Transporters. , 2014, , 1-5.		0
88	Membrane Transporters. , 2014, , 2724-2727.		0
89	Abstract 257: Evaluation of organic cation transporter 1 (OCT1, SLC22A1) as transporter for sorafenib. , 2016, , .		0
90	Abstract 5219: Characterization of the breast cancer resistance protein BCRP in clear cell renal cell carcinoma. , 2017, , .		0